(2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol

It represents a protected C-aryl glucoside structure, in which the glucose moiety is already linked to the substituted phenyl group. In the synthetic pathway, this intermediate undergoes deprotection and functional group modifications (such as removal of methoxy/protecting groups and final purification) to yield dapagliflozin. Its role is crucial because it establishes the correct stereochemistry and carbon–carbon linkage required for the drug’s activity as an SGLT2 inhibitor. The compound (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol is a key intermediate in the synthesis of Dapagliflozin.